Chemistry: molecular biology and microbiology – Maintaining blood or sperm in a physiologically active state...
Reexamination Certificate
1996-11-19
2002-04-30
Scheiner, Laurie (Department: 1648)
Chemistry: molecular biology and microbiology
Maintaining blood or sperm in a physiologically active state...
C435S006120, C536S023720, C536S024300, C536S024330
Reexamination Certificate
active
06379881
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to the diagnosis of variants of the human immunodeficiency virus (HIV), in particular of the type 1 virus (HIV-1). The human immunodeficiency virus, which by now may be better defined as a group of related viruses, is the causative agent for the acquired immuno deficiency syndrome, better known as AIDS.
Apart from the variety of viruses which now have been identified as HIV species, there is also a variety within a single virus species, such as HIV-1.
DESCRIPTION OF THE PRIOR ART
HIV-1 phenotype variability plays a keyrole in the pathogenesis of AIDS. In early asymptomatic infection, virus isolates are generally slow replicating, macrophage-tropic and non syncytium inducing (NSI). In the course of infection, isolates with reduced macrophage-tropic capacity and increased replication rates become predominant (M. Tersmette et al.
J. Virol.
63:2118-2125 1989, H. Schuitemaker et al.
J. Virol.
65:356-363 1991, H. Schuitemaker et al.
J. Virol.
66:1354-1360 1992). In 50% of infected individuals, syncytium inducing (SI) variants arise, coinciding with an accelerated depletion of CD4 positive T-lymphocytes and rapid disease progression (M. Koot et al.
Ann. Int. Med.
118:681-688 1993). In addition, survival time after AIDS diagnosis is reduced for persons with SI isolates (M. Tersmette et al.
Lancet
i:983-985 1989).
Monitoring SI capacity of HIV-1 isolates in seropositive individuals may be used as a prognostic marker for rate of CD4 cell decline and rapid progression to AIDS. The relative risk for disease progression for persons with SI variants is higher than the relative risk of i.e. low CD4 cell numbers or p24 antigenemia and is independent of the latter two markers (M. Koot et al.
Ann. Int. Med.
118:681-688 1993). Apart from the role of HIV-1 biological variability in the natural course of infection, efficacy of zidovudine treatment appeared to be dependent on the biological phenotype of HIV-1. In a study of zidovudine treated asymptomatic individuals at high risk for progression to AIDS, only transient improvement in CD4 cell numbers and response to anti-CD3 monoclonal antibodies in the zidovudine treated persons was observed. However, zidovudine treatment delayed clinical progression significantly in persons who did not develop SI variants (M. Koot et al.
J. Infect. Dis.
168:733-736 1993). Therefore, it is important to determine HIV-1 phenotype of participants in anti-viral drug trials for proper randomization to improve evaluation of efficacy of anti-viral therapy.
So far, SI capacity of isolates from seropositive individuals was monitored using either PHA stimulated peripheral blood mononuclear cells (PBMC) or the MT2 T-cell line as indicator. It was shown that the ability to induce syncytia in PHA stimulated PBMC correlated with the ability to replicate in the MT2 T-cell line for all HIV-1 isolates tested (M. Koot et al.
AIDS
6:49-54 1992). Both methods require specialized laboratory equipment and well trained laboratory personnel since HIV-1 is propagated to high titers. Moreover, the methods require use of purified lymphocytes and are less applicable to whole blood cell samples or serum and plasma samples. In individuals with extremely low CD4 cell numbers (i.e. after AIDS diagnosis) the methods have limited value.
In the search for molecular determinants of HIV-1 SI capacity it was found that the third variable domain (V3) of the envelope molecule gp120 plays an important role in determining SI capacity. Exchange of V3 domains between SI and NSI molecular clones of HIV-1 demonstrated that V3 can confer SI capacity (M. Groenink et al.
Science
260:1513-1516 1993). Sequence analysis of V3 domains from a set of naturally occurring HIV-1 isolates revealed a nearly 100% correlation between HIV-1 phenotype and aminoacid composition of V3 (R. Fouchier et al.
J. Virol.
66:3183-3187 1992). In SI HIV-1 isolates the V3 domain harbours positively charged aminoacid residues (Arginine or Lysine) at positions 306 or 320. In NSI HIV-1 isolates both residues are either uncharged or negatively charged. Site directed mutagenesis at these positions in V3 revealed that presence of positively charged residues at either position indeed confers SI capacity (J. De Jong et al.
J. Virol.
66:757-765 1992).
SUMMARY OF THE INVENTION
The present invention solves the problem of how to make use of these data to discriminate between HIV-1 isolates which do and HIV-1 isolates which do not induce syncytia. The invention provides a method for discriminating between syncytia inducing and non-syncytium inducing variants of the human immunodeficiency virus, wherein the ability to induce syncytium is determined by identifying characterizing nucleotides therefore in either the coding or the non coding strand of the virus. Though the prevalence of the amino acids in HIV-SI variants in comparison with HIV-NSI variants was already known, it was not envisaged how this could be used to discriminate between the two. By Analyzing the difference at the nucleic acid level this discrimination has now become possible in a rapid, easy and safe manner.
In its most general form, the invention described herein presents oligonucleotides with sequences specific for SI HIV-1 isolates that may be used for determination of HIV-1 phenotype in biological materials obtained from seropositive individuals. These oligonucleotides may be variable in length and nucleotide composition, dependent on the technique used for detection, but meet the criteria to discriminate SI from NSI strains based on DNA-sequences responsible for phenotype-specific aminoacid variation at positions 306 and 320 in V3.
In order to determine SI-specific DNA sequence variation first V3 amino acid sequences from 251 isolates obtained from 90 individuals were analyzed for correlation between charge of aminoacid residues at positions 306 and 320 and SI capacity. This correlation was found to be nearly 100% as described earlier (R. Fouchier et al.
J. Virol.
66:3183-3187 1992) and would therefore allow prediction of viral phenotype. Next, we analyzed the frequency of amino acid substitutions at positions 306 and 320 in V3 from SI and NSI isolates and codon usage at these positions, to investigate the phenotype-restricted DNA sequence variation that encodes phenotype-restricted aminoacid variation. In NSI isolates, a Serine or Glycine residue is present at position 306 in nearly 100% of the virus isolates. In SI isolates, this residue is substituted by an Arginine residue in 48% of the sequences. At position 320 3% of the NSI isolates has a Lysine or Arginine residue whereas in the group of SI viruses 43% has such positively charged residues at this position. Given the relatively restricted aminoacid sequence variation at positions 306 and 320, we emphasized that limited DNA sequence variation could account for differences in SI capacity. Analysis of the DNA sequences that encode the amino acid residues at positions 306 and 320 is shown. Although Arginine residues may be coded for by 6 different codons, presence of Arginine residues at position 306 in V3 results from either an AGG or AGA codon in all SI isolates. In NSI isolates, the last nucleotide of the codon at position 306 is either a T or a C (i.e. AGT and AGC encoding Serine and GGT encoding Glycine for 190 out of 191 NSI isolates). Presence of the Arginine and Lysine residues at position 320 results from codons AAA (Lysine) and AGA (Arginine) in all SI isolates. In 181 out of 191 NSI sequences, either G or C is the first nucleotide in codon 320 (i.e. GAA and GAG encoding Glutamic acid, GAT and GAC encoding aspartic acid, and CAA encoding Glutamine). By using an assay according to the present invention that would allow for discrimination of A and G from C and T residues as the last nucleotide in codon 306 and A from G, C and T residues as the first nucleotide in codon 320, analysis of virus isolates from the 90 individuals in this dataset would have resulted in a proper determination of viral phenotype in 94% of the individuals.
There are a number of
Fouchier Ronaldus Adrianus
Schuitemaker Johanna
Akzo Nobel N.V.
Myers Bigel & Sibley & Sajovec
Parkin Jeffrey S.
LandOfFree
Nucleic acids and methods for the discrimination between... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids and methods for the discrimination between..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids and methods for the discrimination between... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2878259